[The treatment of obesity-related hypertension].
The increase in the prevalence of obesity is associated with an increased risk of the development of cardiovascular and renal diseases. Extensive epidemiological studies have demonstrated a relation between the body weight rate and the blood pressure, indicating obesity as one of the factors in hypertension development. Some classes of antihypertensive drugs have potentially adverse effects on some of the metabolic abnormalities that link obesity and hypertension. At the same time, there is no scientific evidence indicating a more efficient group of drugs in the pharmacological management of the obese-related hypertension, therefore the drug treatment choice is based on experience and observations. Based on a particular mechanism leading to the development of hypertension in the obese individuals, the treatment includes the weight reduction associated with the pharmacological management which decreases the risks of both hypertension and obesity.
Skoczylas
Aleksander
A
Oddziału Wewnetrznego Szpitala Powiatowego w Oleśnie.
D000959:Antihypertensive Agents / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000209:etiology; D015897:Comorbidity; D004038:Diet, Reducing; D002149:Energy Intake; D015444:Exercise; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000209:etiology*; D007333:Insulin Resistance; D009765:Obesity / Q000150:complications* / Q000628:therapy; D012307:Risk Factors; D015431:Weight Loss
D000959:Antihypertensive Agents